Top M3541 Secrets
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate various intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Main demo aims were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis patient